UCLA Olympic Analytical Laboratory, David Geffen School of Medicine
Sep 2011 to 2000 Confirmation Analyst UCLA Olympic Analytical Laboratory
Sep 2009 to 2000 Co-supervisor UCLA Olympic Analytical Laboratory, David Geffen School of Medicine
Sep 2009 to Aug 2011 Postdoctoral Fellow UC Berkeley & Lawrence Berkeley National Laboratory
Nov 2007 to Aug 2009 Postdoctoral Fellow National University of Singapore Singapore Aug 2003 to Oct 2007 Graduate Research Assistant National University of Singapore Singapore Jan 2004 to May 2007 Teaching Assistant Tsinghua University
Sep 2000 to Jul 2003 Graduate Research Assistant Tsinghua University
Feb 2001 to Jun 2003 Teaching Assistant Peking University
Sep 1999 to Jul 2000 Undergraduate Research Assistant
Education:
National University of Singapore Singapore Aug 2003 to Oct 2007 PhD in Chemistry Tsinghua University Sep 2000 to Jul 2003 MSc in Chemistry Peking University Sep 1996 to Jul 2000 BSc in Chemistry
Business Records
Name / Title
Company / Classification
Phones & Addresses
Yan Xu
Irn Realty Real Estate Agents and Managers
556 Las Tunas Dr Ste 101, Arcadia, CA 91007
Yan Hua Xu President
Kysin Enterprise Inc
13089 Peyton Dr, Chino Hills, CA 91709
Yan L. Xu President
Western Millwork Supply Co Architecture & Planning · Whol Building Materials
4978 Santa Anita Ave, Temple City, CA 91780 (626) 905-2639
Yan Xu Manager
Lawrence Lake USA, LLC
Yan Xu Managing
Z & Z Capital LLC Real Estate Investment · Investor
Methods For Modulating The Activation Of A Lymphocyte Expressed G Protein Coupled Receptor Involved In Cell Proliferation, Autoimmunity And Inflammation
Owen N. Witte - Sherman Oaks CA Zhigang Weng - Brookline MA Lu Q. Le - Los Angeles CA Janusz H. S. Kabarowski - Los Angeles CA Yan Xu - Pepper Pike OH Kui Zhu - Richmond Heights OH
Assignee:
The Regents of the University of California - Oakland CA
The invention provided herein describes ligands and methods for modulating a G protein-coupled receptor (GPCR), designated G2A, a lymphocyte expressed receptor whose genetic ablation results in the development of autoimmunity. The present disclosure teaches that lysophosphatidylcholine (LPC) is a high affinity ligand for G2A and that sphingosylphosphorylcholine (SPC) is a lower affinity ligand for G2A. As G2A activation is shown to be involved in a variety of physiological processes including cell proliferation, autoimmunity and inflammation, methods which modulate its activity have a variety of diagnostic and therapeutic applications.